Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer: Hayward, California Tuesday, July 15, 2025, 13:00 Hrs [IST] Arcus Bioscience ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

A Taiwanese medical team has developed a new treatment for triple-negative breast cancer (TNBC) that tackles treatment-resistance, National Health Research Institutes (NHRI) president Sytwu Huey-kang ...

Single-molecule magnet could lead to stamp-sized hard drives capable of storing 100 times more data by Australian National University ...

Scientists have discovered that a molecule known for defending animal immune systems called itaconate also plays a powerful role in plants. Researchers showed that itaconate not only exists in ...

Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast ...

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral disease.

How to choose a disease-fighting molecule Drugmakers sort through many modalities to find the best match for their target proteins ...